Skip to content
Biotechnology

Moolec Confirms US Harvest and Promising Yields for Plant-Grown Products GLASO(TM) and Piggy Sooy(TM) in October

Moolec Science SA 2 mins read

LUXEMBOURG / ACCESSWIRE / September 5, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today the harvest confirmation of US campaigns for genetically engineered plant-grown products GLASO™ and Piggy Sooy™ during October 2024.

GLASO™ and Piggy Sooy™ US Harvest Announcement
GLASO™ and Piggy Sooy™ US Harvest Announcement

GLASO™ (gamma-linolenic acid -GLA- in safflower oil) campaign located in Idaho consists of 600 planted acres of genetically modified safflower, mainly for commercial purposes. As a result of the harvest, Moolec is expecting to produce between 300 to 400 tons of safflower seeds that contain high levels of GLA. To allocate most of the upcoming GLASO™ production, Moolec has secured an offtake agreement with a major global CPG company, targeting the US market in 2025. Following a successful and rigorous audit from Moolec's CPG customer, production is set to begin in late 2024.

The Company is also developing a broader commercial strategy to reach larger markets and clients. Moolec's GLASO™ product contains almost 3 times more GLA than conventional sources such as borage and primrose oil, making it the most concentrated GLA oil available on the market.

Piggy Sooy™ (porcine myoglobin in soybean seeds) field trials are being carried out in 3 different US locations: Ohio, Missouri and Iowa. Main purposes for the campaign are product development (sampling), seed increase and gathering of environmental and regulatory data to continue Moolec's US-FDA approval pathway. The Team also projects a remarkable first open field performance for its bioengineered soybean Piggy Sooy™ after recent approval for cultivation from USDA-APHIS. This has set an unprecedented milestone in biotechnology last April, with Moolec becoming the first Molecular Farming company to obtain this kind of clearance for food crops growing animal proteins in US territory.

Chief Technology Officer and Co-Founder Martín Salinas stated: "Our commitment to scaling Moolec's Molecular Farming Technology is demonstrated by our GLASO™ campaign and the field trials of Piggy Sooy™. These efforts not only reinforce our position as pioneers in the industry but also lay the foundation for sustainable solutions in agriculture and biotechnology." He then finished by remarking: "One acre of Piggy Sooy™ could potentially produce pork meat proteins equivalent to 10 pigs, reducing water footprint, land usage and CO2 emissions. This is a clear demonstration on how we promote environmental improvements throughout all our operations. Our aim is to heal the meat production system."

Contact Information

Press & Media
comms@moolecscience.com

Investor Relations
ir@moolecscience.com

Related Files

Moolec Confirms US Harvest And Promising Yields For Plant-Grown Products GLASO™ And Piggy Sooy™ In October - 2024.09.05

SOURCE: Moolec Science

.

View the original press release on newswire.com.

More from this category

  • Biotechnology
  • 06/09/2024
  • 12:00
Cleo Diagnostics Limited. ASX.COV

Cleo Commences U.S. Clinical Trials for its Ovarian Cancer Diagnostic Blood Test

Highlights U.S. clinical trials commenced with first patients enrolled over 8 recruitment centres Trial will validate the use ofCLEO’s ovarian cancer blood test for the U.S. market Pathway set toward FDA submission in CY2025. ___________ MELBOURNE, AUSTRALIA, 6 September 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test. Commencement of U.S. Clinical Trials CLEO’s pivotal FDA-enabling clinical trial has commenced in the United States, with first patients recruited into the study. The trial is designed to benchmarkCLEO’s technology, with…

  • Biotechnology
  • 05/09/2024
  • 23:10
Cambridge Isotope Laboratories, Inc.

Cambridge Isotope Laboratories, Inc. Expands 13C Production Capacity With North Star Project

TEWKSBURY, MA / ACCESSWIRE / September 5, 2024 / Cambridge Isotope Laboratories, Inc. (CIL), the global leader in 13Cand 13C urea production, is excited to announce the startup of its North Star project, significantly increasing the company's production capabilities.CIS AerialCIS Aerial The North Star project commenced in mid-2020 as the world's largest 13C production cascade. After the complex build of phase one finished in March 2024, CIL began to introduce naturally abundant product into the front end of the distillation cascade. With each stage of the cascade, the predicted enrichment has exceeded expectations, and the overall performance has been exceptional.…

  • Biotechnology, Business Company News
  • 04/09/2024
  • 06:05
Blue Ocean Ventures

A Blue Ocean of Opportunity – Blue Ocean Ventures Committed to Bio-Technology Startup SHRMP.bio as it Predicts Significant Future Value of Technologies Enabling High-Tech On-Shore Aquaculture.

[Melbourne, Victoria, Australia]: Venture studio Blue Ocean Ventures today announced that itwill continue supporting its first development project, SHRMP.bio, a biotech startup that aims…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.